True ROI for R&D won't come from the tool that generates 10,000 new ideas. It will come from the tool that confidently tells you which 9,990 to ignore.
Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial. This is an ASCO Meeting Abstract from the 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback